Efinopegdutide (HM12525A): GLP-1/Glucagon Dual Agonist for NASH Research

# Efinopegdutide (HM12525A): GLP-1/Glucagon Dual Agonist for NASH Research

For research purposes only. Not for human use.

What is Efinopegdutide?

Efinopegdutide (HM12525A; also known as MK-6024) is an investigational once-weekly GLP-1 receptor and glucagon receptor dual agonist developed by Hanmi Pharmaceutical and licensed to Merck. It represents a novel approach to treating metabolic liver disease by combining two complementary hormonal pathways in a single molecule.

Unlike traditional GLP-1 monoagonists such as semaglutide (Ozempic/Wegovy), efinopegdutide simultaneously activates both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR), offering a distinct mechanism that targets both metabolic dysfunction and hepatic lipid accumulation. The compound is designed as a modified oxyntomodulin peptide conjugated to a constant region of human immunoglobulin G4 (Fc fragment), with PEGylation (40 kDa PEG chain) enabling once-weekly subcutaneous dosing.

Mechanism of Action: Dual Receptor Activation

The therapeutic benefit of efinopegdutide derives from the complementary actions of its two receptor targets:

GLP-1R Agonism: Activation of the GLP-1 receptor drives multiple metabolic effects including:

• •Reduced appetite and food intake (via CNS satiety signals)
• •Glucose-dependent insulin secretion
• •Delayed gastric emptying
• •Weight loss (body weight reduction observed at ~10% in trials)

GCGR Agonism: Glucagon receptor activation produces hepatic-specific lipid-lowering effects:

• •Reduction in hepatic de novo lipogenesis (DNL)
• •Enhanced mitochondrial beta-oxidation of fatty acids in hepatocytes
• •Increased VLDL secretion to export triglycerides from the liver
• •Improved hepatic insulin sensitivity

The GCGR component is particularly significant for nonalcoholic steatohepatitis (NASH) because glucagon signaling directly counteracts the hepatic lipogenic effects of insulin and stimulates fatty acid oxidation—mechanisms distinct from GLP-1R activation alone. This dual approach addresses both the systemic metabolic dysfunction (via GLP-1R) and the liver-specific fatty acid accumulation (via GCGR) that characterizes NASH pathology.

Clinical Evidence and Trial Data

Phase 2a Results: Superior Liver Fat Reduction

In a Phase 2a active-comparator-controlled trial published in 2023, efinopegdutide demonstrated significantly greater efficacy for liver fat reduction compared to semaglutide (a leading GLP-1 monoagonist):

• •Efinopegdutide 10 mg weekly: 72.7% relative reduction in liver fat content over 24 weeks
• •Semaglutide 1 mg weekly: 35% relative reduction over the same period
• •Placebo: Minimal change in liver fat

This approximately 2-fold superiority in liver fat lowering over 24 weeks suggests that the addition of glucagon receptor agonism provides a meaningful benefit for hepatic steatosis specifically.

Accompanying the liver fat reduction, efinopegdutide-treated patients showed:

• •Normalization of elevated alanine aminotransferase (ALT) levels
• •Weight reduction of approximately 10%
• •Improved markers of fibrosis progression

Phase 2b in Precirrhotic NASH

The Phase 2b randomized, double-blind, placebo-controlled study (MK-6024-013; NCT05877547) evaluated efinopegdutide in adults with biopsy-confirmed precirrhotic NASH (fibrosis stage F1-F3). This trial enrolled 381 participants and completed as of January 2026. Recruitment closure and biopsy readout (histological improvement) remain pending, but this represents a significant advance because liver histology—rather than biomarkers alone—is the gold standard for assessing NASH resolution.

Phase 2 in Compensated Cirrhosis

Recognizing that NASH often progresses to cirrhosis, Merck has also initiated Phase 2 evaluation of efinopegdutide in participants with compensated cirrhosis due to steatohepatitis (MK-6024-017; NCT06465186). This "sicker" population represents the highest-risk NASH phenotype and tests whether the dual agonist approach remains effective and safe in advanced liver disease. Enrollment of 80 patients is complete with trial status active and not recruiting.

Safety and Tolerability Profile

In Phase 2 trials, efinopegdutide demonstrated an acceptable safety profile consistent with GLP-1R agonism:

• •Most common adverse events: Gastrointestinal symptoms (diarrhea 40% in high-dose vs. 19% placebo; nausea 28-42% vs. 23% placebo)
• •Severity: Adverse events were predominantly Grade 1-2 (mild to moderate)
• •Serious events: Four serious adverse events reported; one was drug-related (ulcerative esophagitis in a participant with pre-existing reflux disease)
• •Discontinuations: Five participants discontinued due to adverse events
• •No glucagon signal: Critically, no unexpected safety signals from the GCGR component were observed, allaying initial concerns about potential counter-regulatory hyperglycemia or other glucagon-related toxicities

The GI tolerability profile is similar to other GLP-1 agonists, and no deaths occurred during trials.

Differentiation from GLP-1 Monoagonists and Other NASH Therapies

Versus Semaglutide (Ozempic/Wegovy)

While semaglutide is approved for weight loss and type 2 diabetes, and is increasingly studied off-label for NASH, its liver-specific benefits are indirect—mediated primarily through weight loss and improved systemic glucose control. Efinopegdutide's glucagon receptor agonism provides a direct hepatic mechanism for reducing hepatic lipogenesis and promoting fatty acid oxidation, explaining the superior liver fat reduction observed in the Phase 2a comparator trial.

Versus Tirzepatide (Mounjaro/Zepbound)

Tirzepatide is a GLP-1R/GIP-R dual agonist approved for weight loss and diabetes. While GIP receptor agonism contributes to weight loss and glycemic control, it does not directly address hepatic lipid metabolism in the way that glucagon receptor agonism does. Efinopegdutide's NASH-specific development suggests a more direct targeting of liver disease pathophysiology.

Versus FGF21 Agonists

Some researchers have explored FGF21 receptor agonism (e.g., efruxifermin, pegbelfermin) as an alternative NASH therapy. FGF21 directly improves hepatic fatty acid oxidation and reduces steatosis but lacks the appetite-suppressing and glycemic benefits of GLP-1R activation. Efinopegdutide's combined mechanism integrates metabolic (GLP-1) and hepatic (glucagon) pathways into a single agent, potentially offering a broader therapeutic profile.

Current Regulatory Status and Development Timeline

• •FDA Designation: Fast Track Designation (granted for NASH indication)
• •Clinical Phase: Phase 2 (Phase 2b data pending in precirrhotic NASH; Phase 2 ongoing in compensated cirrhosis)
• •Development: Hanmi Pharmaceutical (original developer) → Merck (licensed developer)
• •Approval Timeline: No Phase 3 initiation announcement as of 2026; full regulatory approval remains investigational

The Fast Track Designation accelerates the FDA review pathway and signals regulatory recognition of an unmet medical need in NASH therapy—particularly important given the lack of approved pharmacotherapies specifically for NASH resolution (resmetirom and VK-2735 represent other recent advances, but the competitive landscape remains limited).

Why GCGR Agonism Matters for NASH Research

NASH pathophysiology involves not just hepatic steatosis but also hepatic inflammation and progressive fibrosis driven by lipotoxicity, oxidative stress, and altered mitochondrial function. Glucagon receptor agonism addresses a mechanistic gap in current GLP-1 monotherapy approaches:

1. Direct mitochondrial activation: GCGR signaling enhances hepatic fatty acid oxidation within mitochondria, reducing intracellular triglyceride accumulation and the lipotoxic damage that fuels inflammation and fibrosis.

2. VLDL export: By promoting hepatic triglyceride export as VLDL, glucagon agonism diverts fatty acids away from lipotoxic accumulation in hepatocytes.

3. Synergy with GLP-1R: While GLP-1R agonism improves systemic insulin sensitivity and glucose control, GCGR activation provides complementary hepatocyte-autonomous benefits. Together, they address both the systemic and organ-specific drivers of NASH.

4. Fibrosis markers: Early data suggest improvements in biomarkers of hepatic inflammation and fibrosis (e.g., FIB-4 index, other serological markers), though liver biopsy data in Phase 2b will provide definitive evidence.

Research Applications and Future Perspectives

Efinopegdutide's dual mechanism has positioned it as a leading investigational agent in the NASH research space:

• •Precirrhotic NASH: Phase 2b biopsy data (expected 2026) will determine whether the drug can induce histological NASH resolution—the gold standard for therapeutic success.
• •Advanced cirrhosis: Testing in compensated cirrhosis addresses the highest-risk NASH phenotype and explores whether the dual agonist approach remains efficacious in end-stage liver disease.
• •Combination therapy: Future research may explore efinopegdutide in combination with other agents (e.g., fibrosis inhibitors, FGF21 agonists) to optimize NASH outcomes.
• •Obesity and metabolic syndrome: As a weight-reducing agent with hepatic benefits, efinopegdutide may be studied in obesity-driven NASH or in metabolic dysfunction-associated fatty liver disease (MAFLD), a broader phenotype.

Safety and Research Considerations

While Phase 2 data support acceptable tolerability, several research considerations remain:

• •GI tolerability: Nausea and diarrhea are more common than with placebo; dose escalation and patient education on tolerability strategies will be important for Phase 3 recruitment.
• •GCGR signal monitoring: Although no unexpected safety signals emerged in Phase 2, larger Phase 3 trials will provide broader safety data on glucagon receptor agonism in this context.
• •Drug interactions: Potential interactions with diabetes medications (insulin, sulfonylureas) should be explored in broader populations.
• •Long-term durability: Sustained liver fat reduction and fibrosis improvement beyond 24-52 weeks remains to be established.

Comparison with Related Compounds

PeptidePrice Platform Resources:

Researchers and clinicians can find detailed comparative data on efinopegdutide and other GLP-1, glucagon, and combination agonists through specialized peptide databases such as PeptidePrice, which aggregates clinical trial data, pricing, and therapeutic positioning for investigational peptides.

Conclusion

Efinopegdutide represents a promising dual-mechanism approach to NASH research, combining GLP-1R and glucagon receptor agonism to address both systemic metabolic dysfunction and liver-specific lipid accumulation. The Phase 2a data demonstrating superior liver fat reduction compared to semaglutide, coupled with acceptable tolerability and the recent grant of Fast Track Designation, position efinopegdutide as a significant contributor to the expanding NASH therapeutic pipeline. Phase 2b biopsy data in precirrhotic NASH and ongoing Phase 2 evaluation in compensated cirrhosis will provide critical evidence for the utility of dual glucagon/GLP-1 agonism in advanced metabolic liver disease. For researchers and clinicians tracking NASH therapeutics, efinopegdutide warrants close attention as a leading candidate for clinical translation.

References and Further Reading

• •Merck Pharmaceutical press releases on efinopegdutide development (2023-2026)
• •EASL 2023 Congress presentations on Phase 2a efficacy and safety data
• •ClinicalTrials.gov registry: NCT05877547 (Phase 2b precirrhotic NASH), NCT06465186 (Phase 2 compensated cirrhosis)
• •Published literature on GLP-1/glucagon dual agonism in metabolic disease and NASH (available via PubMed)

---

Disclaimer: This article is for research and educational purposes only. Efinopegdutide is an investigational compound and is not approved for human use by any regulatory agency. It should not be used as a therapeutic agent outside of approved clinical research settings. Consult qualified healthcare professionals or regulatory authorities for medical or treatment-related questions.